First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
/PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate...